U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C21H30Cl2N2O5
Molecular Weight 461.379
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXLOXIGLUMIDE

SMILES

CCCCCN(CCCOC)C(=O)[C@@H](CCC(O)=O)NC(=O)C1=CC(Cl)=C(Cl)C=C1

InChI

InChIKey=QNQZBKQEIFTHFZ-GOSISDBHSA-N
InChI=1S/C21H30Cl2N2O5/c1-3-4-5-11-25(12-6-13-30-2)21(29)18(9-10-19(26)27)24-20(28)15-7-8-16(22)17(23)14-15/h7-8,14,18H,3-6,9-13H2,1-2H3,(H,24,28)(H,26,27)/t18-/m1/s1

HIDE SMILES / InChI
Molecular Formula C21H30Cl2N2O5
Molecular Weight 461.379
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

Dexloxiglumide is a selective antagonist of cholecystokinin receptor A (CCKA, CCK1). It is the dextro isomeric form of loxiglumide, Dexloxiglumide was investigated for treatment of irritable bowel syndrome. Its development in USA was discontinued.

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Cholecystokinin receptor type A
2
Target ID: P32238
Gene ID: 886.0
Gene Symbol: CCKAR
Target Organism: Homo sapiens (Human)
Antagonist
2778
 7.53 null [pKi]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Phase III
656
Unknown

Approved Use

Unknown
Primary
Preclinical
Unknown

Approved Use

Unknown
PubMed

PubMed

TitleDatePubMed
Dexloxiglumide Rotta Research Lab.
2002 Apr
New and emerging treatments for irritable bowel syndrome and functional dyspepsia.
2002 May
Pharmacokinetics of dexloxiglumide after administration of single and repeat oral escalating doses in healthy young males.
2002 May
Development and validation of a bioanalytical method for the determination of the cholecystokinin type-1 (CCK(1)) receptor antagonist dexloxiglumide in human plasma.
2003 Jan 25
Absorption, distribution, metabolism and excretion of the cholecystokinin-1 antagonist dexloxiglumide in the rat.
2003 Jul-Sep
CCK1 receptor antagonist, dexloxiglumide: effects on human isolated gallbladder. Potential clinical applications.
2003 Sep
Functional dyspepsia: drugs for new (and old) therapeutic targets.
2004 Aug
Absorption, distribution, metabolism and excretion of the cholecystokinin-1 antagonist dexloxiglumide in the dog.
2004 Jan-Mar
Cholecystokinin pathways modulate sensations induced by gastric distension in humans.
2004 Jul
Interaction of dexloxiglumide, a cholecystokinin type-1 receptor antagonist, with human cytochromes P450.
2004 May
Pharmacological analysis of CCK2 receptors up-regulated using engineered transcription factors.
2005 Jul 15
Effect of CCK-1 antagonist, dexloxiglumide, in female patients with irritable bowel syndrome: a pharmacodynamic and pharmacogenomic study.
2005 Mar
Effect of multiple-dose dexloxiglumide on the pharmacokinetics of oral contraceptives in healthy women.
2005 Mar
Effect of azole antifungals ketoconazole and fluconazole on the pharmacokinetics of dexloxiglumide.
2005 Nov
Basic and clinical pharmacology of new motility promoting agents.
2005 Oct
The single-dose pharmacokinetics of the novel CCK1 receptor antagonist, dexloxiglumide, are not influenced by age and gender.
2005 Sep
Pharmacokinetic profile of dexloxiglumide.
2006
Signal transduction pathways mediating CCK-8S-induced gastric antral smooth muscle contraction.
2006
Use of novel prokinetic agents to facilitate return of gastrointestinal motility in adult critically ill patients.
2006 Aug
A novel, quantitative bio-assay for cholecystokinin type-1 receptor activity in the anaesthetised rat.
2006 Jul-Aug
The relationship between gastric emptying, plasma cholecystokinin, and peptide YY in critically ill patients.
2007
Effect of CCK-1 receptor blockade on ghrelin and PYY secretion in men.
2007 Apr
Gateways to clinical trials.
2007 Jan-Feb
3-[5-(3,4-Dichloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-m-tolyl-propionate (JNJ-17156516), a novel, potent, and selective cholecystokinin 1 receptor antagonist: in vitro and in vivo pharmacological comparison with dexloxiglumide.
2007 Nov
Role of CCK and potential utility of CCK1 receptor antagonism in the treatment of pancreatitis induced by biliary tract obstruction.
2008 Apr
Duodenal phytohaemagglutinin (red kidney bean lectin) stimulates gallbladder contraction in humans.
2008 Jul
Regulation of fat-stimulated neurotensin secretion in healthy subjects.
2008 May
Prokinetic drugs for feed intolerance in critical illness: current and potential therapies.
2009 Jun
Oral and gastrointestinal sensing of dietary fat and appetite regulation in humans: modification by diet and obesity.
2010
Defining the role of cholecystokinin in the lipid-induced human brain activation matrix.
2010 Apr
Role of fat hydrolysis in regulating glucagon-like Peptide-1 secretion.
2010 Feb
Association of CCK(1) Receptor Gene Polymorphisms and Irritable Bowel Syndrome in Korean.
2010 Jan
Neuropathy, retinopathy, and glucose-lowering treatments.
2010 Jun
Current insights in to the pathophysiology of Irritable Bowel Syndrome.
2010 May 13
Gastric emptying of hexose sugars: role of osmolality, molecular structure and the CCK₁ receptor.
2010 Nov
Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome.
2013 Apr
Patents

Patents

20040224983
1
20040266989
1
20050043310
1
20060014817
1
20060018933
35
20060154987
1
20060258593
1

Sample Use Guides

In Vivo Use Guide
In phase 2 clinical trials for treatment of constipation predominant irritable bowel syndrome dexloxiglumide was administered at doses 200 mg tid.
Route of Administration: Oral
In Vitro Use Guide
Binding of dexloxiglumide to cholecystokinin receptor 1 (CCK1) was studied using radioligand binding assay. CHO cells were transfected with CCK1. Cell membanes rere incubated with 60 pM 125I-BH-CCK-8S (Bolton Hunter-sulfated cholecystokinin octapeptide), and treated with varying concentration of dexloxiglumide. The bound radioactivity was separated by filtration, and radioactivity retained on the filters was measured by liquid scintillation counting.
Substance Class Chemical
Created
by admin
on Sat Dec 16 16:27:01 GMT 2023
Edited
by admin
on Sat Dec 16 16:27:01 GMT 2023
Record UNII
69DY40RH9B
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEXLOXIGLUMIDE
INN   WHO-DD  
INN  
Official Name English
LOXIGLUMIDE (R)-FORM
MI  
Common Name English
LOXIGLUMIDE (R)-FORM [MI]
Common Name English
CR-2017
Code English
(+)-LOXIGLUMIDE
Common Name English
LOXIGLUMIDE, (R)-
Common Name English
dexloxiglumide [INN]
Common Name English
(R)-4-(3,4-DICHLOROBENZAMIDO)-N-(3-METHOXYPROPYL)-N-PENTYLGLUTARAMIC ACID
Systematic Name English
Dexloxiglumide [WHO-DD]
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C29701
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
NCI_THESAURUS C28197
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
Code System Code Type Description
NCI_THESAURUS
C96871
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
PRIMARY
MESH
C103490
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
PRIMARY
WIKIPEDIA
DEXLOXIGLUMIDE
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
PRIMARY
DRUG BANK
DB04856
Created by admin on Sat Dec 16 16:27:01 GMT 2023 , Edited by admin on Sat Dec 16 16:27:01 GMT 2023
PRIMARY
MERCK INDEX
m6916
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
PRIMARY Merck Index
CAS
119817-90-2
Created by admin on Sat Dec 16 16:27:01 GMT 2023 , Edited by admin on Sat Dec 16 16:27:01 GMT 2023
PRIMARY
EVMPD
SUB07036MIG
Created by admin on Sat Dec 16 16:27:01 GMT 2023 , Edited by admin on Sat Dec 16 16:27:01 GMT 2023
PRIMARY
ChEMBL
CHEMBL550781
Created by admin on Sat Dec 16 16:27:01 GMT 2023 , Edited by admin on Sat Dec 16 16:27:01 GMT 2023
PRIMARY
PUBCHEM
65937
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
PRIMARY
SMS_ID
100000083408
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
PRIMARY
INN
6782
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
PRIMARY
FDA UNII
69DY40RH9B
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
PRIMARY
EPA CompTox
DTXSID50152604
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
PRIMARY
DRUG CENTRAL
834
Created by admin on Sat Dec 16 16:27:02 GMT 2023 , Edited by admin on Sat Dec 16 16:27:02 GMT 2023
PRIMARY
Related Record Type Details
CHOLECYSTOKININ RECEPTOR TYPE A
TARGET -> INHIBITOR
Structure of LOXIGLUMIDE
RACEMATE -> ENANTIOMER
Related Record Type Details
Structure of DEXLOXIGLUMIDE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966